Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug ...

Nice 23andMe sale hearing ya got there — shame if something happened to it, say attorneys for co-founder and former CEO who ...

The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...

Despite advancements in microbial safety strategies, agri-food systems remain vulnerable to microbial infections, posing significant threats to food safety, ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

Regeneron is buying bankrupt genetic testing firm 23andMe, which helped usher in the era of consumer DNA test kits nearly two ...

But what if that timeline wasn’t inevitable? What if women were able to delay the onset of menopause or, more provocatively, end it all together? Medical researchers are tackling those questions, ...

Here are the key moments to know from its history. Biotech was born in the Bay Area 50 years ago. Here's what lies ahead This startup is on a mission to fight lung cancer early on This startup is ...